$876.57 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter

Wall Street analysts predict that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will post $876.57 million in sales for the current quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $847.72 million to $900.89 million. Alexion Pharmaceuticals reported sales of $831.00 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.5%. The business is scheduled to report its next earnings results on Thursday, February 15th.

On average, analysts expect that Alexion Pharmaceuticals will report full year sales of $876.57 million for the current financial year, with estimates ranging from $3.49 billion to $3.54 billion. For the next fiscal year, analysts expect that the business will post sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same quarter last year, the business earned $1.23 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year.

ALXN has been the subject of several research reports. TheStreet lowered shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research report on Tuesday, October 31st. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Royal Bank of Canada initiated coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective for the company. Finally, Credit Suisse Group reiterated a “buy” rating and set a $166.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $155.70.

Several institutional investors have recently added to or reduced their stakes in the company. Rathbone Brothers plc lifted its holdings in Alexion Pharmaceuticals by 2.5% during the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 50 shares in the last quarter. Evercore Wealth Management LLC lifted its holdings in Alexion Pharmaceuticals by 8.1% during the 2nd quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 125 shares in the last quarter. Wealthsource Partners LLC lifted its holdings in Alexion Pharmaceuticals by 4.4% during the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock valued at $365,000 after buying an additional 126 shares in the last quarter. National Asset Management Inc. lifted its holdings in Alexion Pharmaceuticals by 5.1% during the 2nd quarter. National Asset Management Inc. now owns 3,345 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 162 shares in the last quarter. Finally, Tudor Investment Corp ET AL lifted its holdings in Alexion Pharmaceuticals by 2.4% during the 2nd quarter. Tudor Investment Corp ET AL now owns 7,207 shares of the biopharmaceutical company’s stock valued at $877,000 after buying an additional 170 shares in the last quarter. Hedge funds and other institutional investors own 94.26% of the company’s stock.

Alexion Pharmaceuticals (ALXN) traded down $0.67 during mid-day trading on Friday, reaching $119.59. 1,082,217 shares of the company’s stock traded hands, compared to its average volume of 1,989,982. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $26,867.24, a price-to-earnings ratio of 53.39, a P/E/G ratio of 1.31 and a beta of 1.18.

ILLEGAL ACTIVITY NOTICE: “$876.57 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/876-57-million-in-sales-expected-for-alexion-pharmaceuticals-inc-alxn-this-quarter-2.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply